Leprosy in Iran: An analysis of 195 cases from 1994-2009

Journal of the Pakistan Medical Association

Volumn 61, Issue 6, 2011, Pages 558-561

  Golfurushan, Farideh ^a   Sadeghi, Mohamad ^a   Goldust, Mohamad ^a   Yosefi, Neda ^a  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Dermatitis; Infectious disease; Lepromatous; Mycobacterium; Ulnar nerve

Indexed keywords

CLOFAZIMINE; DAPSONE; RIFAMPICIN;

ADULT; ARTICLE; CHILD; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE REGISTRY; FEMALE; HAIR LOSS; HUMAN; IRAN; LEPROMATOUS LEPROSY; LEPROMIN TEST; LEPROSY; MAJOR CLINICAL STUDY; MALE; MULTIBACILLARY LEPROSY; PAUCIBACILLARY LEPROSY; PERIPHERAL NERVE INJURY; PREVALENCE; RARE DISEASE; SCHOOL CHILD; SKIN DEFECT; SKIN EXAMINATION; SKIN INFLAMMATION; TUBERCULOID LEPROSY; ULNAR NERVE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; BIOPSY; CHILD; FEMALE; HUMANS; IRAN; LEPROSTATIC AGENTS; LEPROSY; MALE; MIDDLE AGED; POPULATION SURVEILLANCE; PREVALENCE; SEX DISTRIBUTION; SKIN; YOUNG ADULT;

EID: 79957689099     PISSN: 00309982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Lockwood DNJ. Leprosy. In: Burns DA, Breathnach SM, Cox NH, Griffiths CEM, editors. Rook's textbook of dermatology, vol 2. 7th ed. Oxford: Blackwell Publishing, 2004; pp 29.1-29.21.
2. Robertson J. Leprosy, Historical. International Encyclopedia of Public Health, 2008; pp 65-74
3. Global leprosy situation. Wkly Epidemiol Rec 2005; 80: 289-95.
4. Boggild AK, Keystone JS, Kain KC. Leprosy: A primer for Canadian physicians. CMAJ 2004; 170: 71-8.
5. Van Brakel WH, Feenstra P, Saunderson PR. Leprosy. In: Quan S, Heggenhougen K eds. International Encyclopedia of Public Health. Academic Press, 2008; pp 56-65.
6. Bongiorno MR, Pistone G, Noto S. Tuberculoid leprosy and Type 1 lepra reaction. Travel Med Infect Dis 2008; pp 6: 311-4.
7. Bryceson A, Pfaltzgraff RE. Leprosy. Clinical Pathology, Symptoms and Signs. In: Hastings RC, ed. Medicine in the Tropics, 3rd ed, Edinburgh: Churchill-Livingstone; 1990; pp 11-55.
8. Croft RP, Nicholls PG, Steyerberg EW, Richardus JH, Cairns W, Smiths. A clinical prediction rule for nerve-function impairment in leprosy patients. Lancet, 2000; 355: 1603-6.
9. Sabin TD, Swift TR. Leprosy. Encyclopedia of the Neurological Sciences 2003; pp 775-80.
10. Rabhan NB, Waldorf DS. Lepromatous Leprosy. Lancet, 1968; 292: pp 917.
11. Boggild AK, Correia JD, Keystone JS, Kain KC. Leprosy in Toronto: An analysis of 184 imported cases. CMAJ 2004; 170: 55-9.
12. Toweir AA, Chaudhary RC. Review of Leprosy cases in Benghazi, Libyan Arab Jamahiriya, 1994-98. East Mediterr Health J 2000; 6: 1098-102.
13. Kaplan G, Cohn ZA. Cellular immunity in lepromatous and tuberculoid leprosy. Immunol Letters 1985; 11: 205-9.
14. Kinnear Brown JA, Stone MM. Lepromin conversion following infection with leprosy. Trans R Soc Trop Med Hyg 1961; 55: 443-5.
15. Skacel M, Antunes SL, Rodrigues MM, J.A. et al. The diagnosis of Leprosy among patients with symptoms of peripheral neuropathy without cutaneous lesions: a follow-up study. Arq Neuropsiquiatr 2009; 58: 800-7.
16. Millan JP, Moulia-Pelat JP. Antagonism between dapsone and rifampicin in experimental Mycobacterium leprae infections in mice. Res Microbiol 1989; 2: 143-50.
17. Yawalkar SJ, Mcdougall AC, Languillon J, Ghosh S, Hajra SK, Opromolla DV, et al. Once-monthly rifampicin plus daily dapsone in initial treatment of lepromatous leprosy. Lancet 1982; 8283: 1199-202.
18. Cambau E, Perani E, Guillemin I, Jamet P, Ji B. Multidrug-resistance to dapsone, rifampicin, and ofloxacin in Mycobacterium leprae. Lancet 1997; 349: 103-4.